Gemcitabine, the current standard-of-care therapy for pancreatic cancer, has limited clinical benefit alone, and recent work has indicated that induction of NF-κB activity by gemcitabine may be involved in chemoresistance [9,17-20]. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.